South African Study to Compare J&J, Pfizer Covid-19 Boosters
(Bloomberg) -- Researchers have started recruiting South African health workers to take part in a vaccine trial that will compare the use of Johnson & Johnson and Pfizer Inc. Covid-19 shots as boosters.Â
The health workers being targeted for the study were part of an initial trial known as Sisonke that saw almost half a million people given an initial dose of J&J's vaccine.Â
The trial, which will be carried out by Johannesburg's Wits Reproductive Health and HIV Institute, will run for six months, according to an invitation to potential participants. Participants will be randomly allocated a full or half dose of a vaccine made by either J&J, or Pfizer and BioNTech SE.Â
A booster trial using a second J&J dose has already been run on some Sisonke participants. The government has in recent weeks begun offering both J&J and Pfizer boosters, with the stipulation that those administered with the vaccine receive the same inoculation they got initially.Â
The new study has been named Booster After Sisonke Study, or BaSiS.Â
©2022 Bloomberg L.P.
-
India's Troika Of Good Luck | Joining The Dots
A weaker Trump, a cooling AI trade and resilient earnings have put Indian markets back in favour. Rising inflation could spoil the party.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
